Tadalafil Tablet, Film Coated
Product Images NDC 72789-430

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 72789-430). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789430 Label (72789430)

Label for tadalafil USP 10 mg film-coated tablets by PD-Rx Pharmaceuticals, Inc. The label indicates a package of 90 tablets. It includes the NDC 72789-430-90 and details such as lot number I24C34, expiration date 03/2027, and directions space for dosing. There is a warning to keep out of reach of children and a barcode, along with the company address in Oklahoma City, OK.*

FDA Label Image

Chemical Structure (Tadalafil 1)

Chemical structure of Tadalafil, the active ingredient in the product tadalafil 10 mg oral film-coated tablets by PD-Rx Pharmaceuticals, Inc. The diagram shows the molecular arrangement including fused rings and functional groups typical of Tadalafil.*

FDA Label Image

Tadalafil-tablets-figure-1 (Tadalafil 2)

A four-panel line graph depicting the differences in blood pressure measurements between tadalafil and placebo over time. The panels illustrate standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure changes in mmHg from 0 to 96 hours.*

FDA Label Image

Tadalafil-tablets-figure-2 (Tadalafil 3)

This image contains two line graphs showing the effects of tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on standing and supine systolic blood pressure (BP) over 24 hours post-dose. The graphs plot systolic BP changes in mmHg on the vertical axis against time in hours on the horizontal axis, comparing the two treatment groups.*

FDA Label Image

Tadalafil-tablets-figure-3 (Tadalafil 4)

A line graph depicting systolic blood pressure (mmHg) changes over 12 hours following administration of tadalafil or placebo with doxazosin. It compares four groups: 20 mg tadalafil at 08:00 with 8 mg doxazosin, placebo at 08:00 with 8 mg doxazosin, 20 mg tadalafil at 20:00 with 8 mg doxazosin, and placebo at 20:00 with 8 mg doxazosin. The x-axis indicates time after administration, and the y-axis shows systolic BP changes.*

FDA Label Image

Tadalafil-tablets-figure-4 (Tadalafil 5)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for different dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 days. The graph includes error bars indicating variability at each time point, with concentration decreasing over time for all groups.*

FDA Label Image

Table 5 (Tadalafil 6)

A line chart comparing changes from baseline in IPSS Total Score over 12 weeks of treatment for tadalafil 5 mg and placebo groups. The x-axis represents treatment duration in weeks, and the y-axis shows change in IPSS Total Score, with tadalafil showing a greater reduction than placebo throughout the study period.*

FDA Label Image

Table 6 (Tadalafil 7)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment comparing Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the change in score, with Tadalafil demonstrating a greater decrease than placebo. Statistical significance is noted at p<0.01.*

FDA Label Image

Tadalafil-tablets-figure-7 (Tadalafil 8)

A line graph showing the least squares mean change from baseline over weeks of therapy (0, 4, 12, 26) comparing Tadalafil/Finasteride and Placebo/Finasteride. The vertical axis measures LS mean change from baseline, with Tadalafil/Finasteride showing a greater decrease than placebo at each time point. Statistical significance markers (p<0.001, p<0.05) are noted.*

FDA Label Image

Image 8 (Tadalafil 9)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment duration between Tadalafil 5 mg and placebo groups. The graph shows treatment duration in weeks on the x-axis and change in IPSS total score on the y-axis, with Tadalafil demonstrating a greater decrease in score over time compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.